Coherus restructures, axes 51 staffers in wake of an FDA rejection of its knockoff of Amgen’s Neulasta
Just two weeks after the FDA spurned Coherus’ application to sell a knockoff of Amgen’s Neulasta, the biosimilar maker has come back with a plan to ax 51 staffers — about 30% of its employees — as it hunkers down to weather the derailment.
The news earlier this month marked a reprieve for Amgen, which counts this drug as one of its mainstays. Amgen has been both lucky and good at holding off biosimilar competition to its aging flagship drugs, with Pfizer getting its second delay after the FDA found problems with its manufacturing site in Kansas. And that pitch had been blessed by inside and outside experts at the agency.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.